ArticleScientific reports2025
eSolubilized amniotic membrane ECM as a promising biological surface treatment approach for 3D-printed bone tissue engineering scaffolds.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metal coordination at biological interfaces: Mechanisms, therapeutics, and translation.Materials today. Bio · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, the fused deposition modeling method was used to fabricate 3D-printed polycaprolactone (PCL). This study introduces a cost-effective post-fabrication treatment by using a Solubilized Amniotic Membrane (SAM) extracellular matrix (ECM) as a biological surface modifier. The employment of SAM provides an easy approach to overcoming the current challenges in the way of using fresh, cryopreserved, or dehydrated tissue. Four groups were included in this study, including neat PCL, oxygen plasma-treated PCL, SAM 0.001%w/v (SAM1), and SAM 0.005%w/v (SAM5). According to the SEM images, the diameter of each 3D-printed filament and filament distance were around 573 μm and 372 μm, respectively. The FTIR-ATR spectra confirmed the presence of amide groups in specimen, containing SAM. A higher weight loss rate was obtained for oxygen plasma-treated PCL and SAM-containing samples than neat PCL. The results of in vitro studies revealed that the optimized content of SAM (SAM 5) could promote the osteogenesis potency of Wharton-Jelly Mesenchymal Stem Cells (WJ-MSCs), cultured on the 3D-printed scaffolds in terms of alkaline phosphatase activity, calcium deposition and real-time PCR assessment of alkaline phosphatase, osteocalcin, and osteonectin. Also, in vivo, the collagen content in the control group and SAM 5 was 30.89 ± 1.73 and 44.24 ± 2.91, respectively. According to the Micro-CT assessment, the bone volume fraction was remarkably improved in the presence of SAM5 as it increased from 36.52 ± 1.56% in the control group to 42.66 ± 2.17% in SAM5. The results of the present study provide a promising surface modification approach by employing SAM for the future of bone tissue engineering scaffolds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.